NASDAQ:AVDLAvadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AVDL stock has increased by 0.9% and is now trading at $8.06. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avadel Pharmaceuticals.

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Avadel Pharmaceuticals.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) announced its earnings results on Monday, May, 11th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.25. The firm earned $12.24 million during the quarter, compared to the consensus estimate of $10.25 million. View Avadel Pharmaceuticals' earnings history.

Avadel Pharmaceuticals updated its first quarter 2020 Pre-Market earnings guidance on Thursday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10 million, compared to the consensus revenue estimate of $8.35 million.

6 Wall Street analysts have issued 12 month price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $6.00 to $18.00. On average, they expect Avadel Pharmaceuticals' share price to reach $11.92 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price. View analysts' price targets for Avadel Pharmaceuticals.

Media coverage about AVDL stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAvadel Pharmaceuticals.

Avadel Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 6,500,000 shares, an increase of 47.7% from the April 15th total of 4,400,000 shares. Based on an average daily volume of 730,600 shares, the short-interest ratio is currently 8.9 days. Approximately 18.8% of the shares of the stock are short sold. View Avadel Pharmaceuticals' Current Options Chain.

Some companies that are related to Avadel Pharmaceuticals include ZEALAND PHARMA/S (ZEAL), Supernus Pharmaceuticals (SUPN), Cytokinetics (CYTK), Phoenix Tree (IMAB), Revance Therapeutics (RVNC), Phathom Pharmaceuticals (PHAT), MacroGenics (MGNX), Arcturus Therapeutics (ARCT), Myovant Sciences (MYOV), I-Mab (ARQT), Aimmune Therapeutics (AIMT), Kiniksa Pharmaceuticals (KNSA), Rocket Pharmaceuticals (RCKT), Esperion Therapeutics (ESPR) and Enanta Pharmaceuticals (ENTA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and China Unicom (Hong Kong) (CHU).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (9.55%), Cowen AND Company LLC (4.05%), VR Adviser LLC (2.82%), Invesco Ltd. (1.96%), Tekla Capital Management LLC (1.51%) and Driehaus Capital Management LLC (1.31%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View institutional ownership trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Tekla Capital Management LLC, UBS Group AG, and Investors Asset Management of Georgia Inc. GA ADV. View insider buying and selling activity for Avadel Pharmaceuticals.

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Cowen AND Company LLC, VR Adviser LLC, Invesco Ltd., Driehaus Capital Management LLC, Ghost Tree Capital LLC, Arlington Capital Management Inc., and Bailard Inc.. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, and Michael S Anderson. View insider buying and selling activity for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $8.06.

Avadel Pharmaceuticals has a market capitalization of $301.85 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.

The official website for Avadel Pharmaceuticals is www.avadel.com.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]